Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Chief Medical Officer | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kymera Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,134 |
Ending reported balance
After 2026-03-04 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-03-02 · Grant · Acquired 17,650 · Balance 127,642 F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. Row 2 · 2026-03-02 · Sale · Disposed 1,510 · Balance 126,132 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.11 to $88.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-03-02 · Sale · Disposed 1,055 · Balance 125,077 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.11 to $89.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-03-02 · Sale · Disposed 3,048 · Balance 122,029 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $90.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-03-04 · Sale · Disposed 492 · Balance 121,537 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.36 to $84.3338, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2026-03-04 · Sale · Disposed 2,519 · Balance 119,018 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.4475 to $85.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2026-03-04 · Sale · Disposed 1,437 · Balance 117,581 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.45 to $86.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 8 · 2026-03-04 · Sale · Disposed 447 · Balance 117,134 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.48 to $86.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.10 · Expires 2036-03-01 | Direct | 35,300 |
Reported balance
After 2026-03-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-03-02 · Grant · Acquired 35,300 · Balance 35,300 F10: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.
F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.11 to $88.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.11 to $89.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $90.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.36 to $84.3338, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.4475 to $85.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.45 to $86.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.48 to $86.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 447 | $86.62 | $38,721.24 |
DisclosureSEC source: 0001193125-26-091983 · ownership.xml · nonDerivative · entry 8 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,134 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.48 to $86.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,437 | $85.78 | $123,266.87 |
DisclosureSEC source: 0001193125-26-091983 · ownership.xml · nonDerivative · entry 7 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,581 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.45 to $86.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,519 | $85.04 | $214,206.69 |
DisclosureSEC source: 0001193125-26-091983 · ownership.xml · nonDerivative · entry 6 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,018 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.4475 to $85.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 492 | $84.00 | $41,326.28 |
DisclosureSEC source: 0001193125-26-091983 · ownership.xml · nonDerivative · entry 5 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,537 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.36 to $84.3338, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 35,300 | $0.00 Strike: $90.10 | $0.00 |
DisclosureSEC source: 0001193125-26-091983 · ownership.xml · derivative · entry 9 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,300 Underlying: Common Stock · 35,300 shares Expires 2036-03-01 F10 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,048 | $89.66 | $273,275.76 |
DisclosureSEC source: 0001193125-26-091983 · ownership.xml · nonDerivative · entry 4 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,029 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $90.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,055 | $88.50 | $93,367.92 |
DisclosureSEC source: 0001193125-26-091983 · ownership.xml · nonDerivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,077 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.11 to $89.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,510 | $87.75 | $132,503.86 |
DisclosureSEC source: 0001193125-26-091983 · ownership.xml · nonDerivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,132 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.11 to $88.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantCommon Stock | 17,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-091983 · ownership.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,642 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 23:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 49,307 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001193125-25-311503 · ownership.xml · derivative · entry 8 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,083 Underlying: Common Stock · 49,307 shares Expires 2030-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. F7 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 23:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,400 | $92.19 | $129,066.00 |
DisclosureSEC source: 0001193125-25-311503 · ownership.xml · nonDerivative · entry 7 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,992 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 23:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,300 | $91.46 | $301,830.87 |
DisclosureSEC source: 0001193125-25-311503 · ownership.xml · nonDerivative · entry 6 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,392 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.04 to $92.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 23:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 8,562 | $90.12 | $771,629.70 |
DisclosureSEC source: 0001193125-25-311503 · ownership.xml · nonDerivative · entry 5 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,692 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.905 to $90.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 23:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,929 | $89.43 | $351,356.33 |
DisclosureSEC source: 0001193125-25-311503 · ownership.xml · nonDerivative · entry 4 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,254 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.87 to $89.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 23:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 18,357 | $88.02 | $1,615,810.68 |
DisclosureSEC source: 0001193125-25-311503 · ownership.xml · nonDerivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,183 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.77 to $88.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 23:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 13,759 | $87.37 | $1,202,138.96 |
DisclosureSEC source: 0001193125-25-311503 · ownership.xml · nonDerivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,540 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.77 to $87.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2025 Filed Dec 8, 2025 23:09 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 49,307 | $5.33 | $262,806.31 |
DisclosureSEC source: 0001193125-25-311503 · ownership.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 21:28 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,210 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001193125-25-240430 · ownership.xml · derivative · entry 8 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,210 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. F6 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 21:28 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,999 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001193125-25-240430 · ownership.xml · derivative · entry 7 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,999 shares Expires 2028-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. F6 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 21:28 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 6,453 | $63.09 | $407,099.12 |
DisclosureSEC source: 0001193125-25-240430 · ownership.xml · nonDerivative · entry 6 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,992 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.02 to $63.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 21:28 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 14,896 | $62.72 | $934,326.28 |
DisclosureSEC source: 0001193125-25-240430 · ownership.xml · nonDerivative · entry 5 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,445 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.01 to $63.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 21:28 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 8,963 | $61.49 | $551,160.86 |
DisclosureSEC source: 0001193125-25-240430 · ownership.xml · nonDerivative · entry 4 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,341 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.01 to $62.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 21:28 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 29,264 | $60.37 | $1,766,667.68 |
DisclosureSEC source: 0001193125-25-240430 · ownership.xml · nonDerivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,304 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 21:28 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 22,210 | $2.08 | $46,196.80 |
DisclosureSEC source: 0001193125-25-240430 · ownership.xml · nonDerivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 169,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 21:28 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 28,999 | $1.31 | $37,988.69 |
DisclosureSEC source: 0001193125-25-240430 · ownership.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 21:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 673 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001193125-25-239144 · ownership.xml · derivative · entry 5 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,210 Underlying: Common Stock · 673 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. F2 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 21:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 800 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001193125-25-239144 · ownership.xml · derivative · entry 4 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,999 Underlying: Common Stock · 800 shares Expires 2028-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. F2 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 21:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,114 | $60.00 | $186,840.00 |
DisclosureSEC source: 0001193125-25-239144 · ownership.xml · nonDerivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,359 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 21:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 673 | $2.08 | $1,399.84 |
DisclosureSEC source: 0001193125-25-239144 · ownership.xml · nonDerivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. Read SEC document |
| October 13, 2025 Filed Oct 14, 2025 21:11 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 800 | $1.31 | $1,048.00 |
DisclosureSEC source: 0001193125-25-239144 · ownership.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 2, 2025 adopted by the reporting person. Read SEC document |
| March 03, 2025 Filed Mar 3, 2025 23:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0000950170-25-031144 · ownership.xml · derivative · entry 4 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-03-02 F5 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 03, 2025 Filed Mar 3, 2025 23:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,045 | $31.00 | $32,399.81 |
DisclosureSEC source: 0000950170-25-031144 · ownership.xml · nonDerivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.90 to $31.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 3, 2025 23:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 4,695 | $30.33 | $142,385.73 |
DisclosureSEC source: 0000950170-25-031144 · ownership.xml · nonDerivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,045 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 3, 2025 23:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-031144 · ownership.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,740 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| July 16, 2024 Filed Jul 16, 2024 22:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,145 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000950170-24-084003 · ownership.xml · derivative · entry 7 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,883 Underlying: Common Stock · 23,145 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. F5 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| July 16, 2024 Filed Jul 16, 2024 22:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 9,864 | $46.10 | $454,695.88 |
DisclosureSEC source: 0000950170-24-084003 · ownership.xml · nonDerivative · entry 5 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,470 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.02 to $46.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 16, 2024 Filed Jul 16, 2024 22:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 13,281 | $45.59 | $605,521.96 |
DisclosureSEC source: 0000950170-24-084003 · ownership.xml · nonDerivative · entry 4 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,604 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.02 to $46.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 16, 2024 Filed Jul 16, 2024 22:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 23,145 | $2.08 | $48,141.60 |
DisclosureSEC source: 0000950170-24-084003 · ownership.xml · nonDerivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. Read SEC document |
| July 15, 2024 Filed Jul 16, 2024 22:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,455 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000950170-24-084003 · ownership.xml · derivative · entry 6 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,028 Underlying: Common Stock · 16,455 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. F5 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| July 15, 2024 Filed Jul 16, 2024 22:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 16,455 | $45.15 | $742,925.15 |
DisclosureSEC source: 0000950170-24-084003 · ownership.xml · nonDerivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,740 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 15, 2024 Filed Jul 16, 2024 22:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 16,455 | $2.08 | $34,226.40 |
DisclosureSEC source: 0000950170-24-084003 · ownership.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. Read SEC document |
| March 04, 2024 Filed Mar 4, 2024 23:21 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 216 | $43.26 | $9,343.38 |
DisclosureSEC source: 0000950170-24-025101 · ownership.xml · nonDerivative · entry 4 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,740 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.065 to $44.025, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 4, 2024 23:21 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,106 | $42.39 | $46,885.99 |
DisclosureSEC source: 0000950170-24-025101 · ownership.xml · nonDerivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,956 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.06 to $43.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 4, 2024 23:21 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,022 | $41.41 | $83,738.10 |
DisclosureSEC source: 0000950170-24-025101 · ownership.xml · nonDerivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,062 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.05 to $41.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:21 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 146,250 | $0.00 Strike: $43.50 | $0.00 |
DisclosureSEC source: 0000950170-24-025101 · ownership.xml · derivative · entry 5 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,250 Underlying: Common Stock · 146,250 shares Expires 2034-02-28 F6 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:21 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantCommon Stock | 24,375 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025101 · ownership.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,084 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:34 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 400 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000950170-24-023168 · ownership.xml · derivative · entry 3 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,483 Underlying: Common Stock · 400 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. F2 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:34 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 400 | $45.00 | $18,000.00 |
DisclosureSEC source: 0000950170-24-023168 · ownership.xml · nonDerivative · entry 2 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,709 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:34 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 400 | $2.08 | $832.00 |
DisclosureSEC source: 0000950170-24-023168 · ownership.xml · nonDerivative · entry 1 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person. Read SEC document |
| February 09, 2024 Filed Feb 10, 2024 00:47 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 46,137 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000950170-24-013482 · ownership.xml · derivative · entry 4 Gollob Jared · CIK 0001821198 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,883 Underlying: Common Stock · 46,137 shares Expires 2029-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.